Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001708599-26-000068
What the release said
Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics reported third quarter 2026 results, with operating expenses of $8.0 million and a net loss attributable to common stockholders of $7.9 million, or $(0.31) per basic and diluted share.¶1¶2¶3
In September 2026, the independent Safety Monitoring Committee recommended advancement of SER-252 to Cohort 2 of the registrational study, and dosing in Cohort 2 has been initiated.¶4¶5
Topline data from the single-ascending-dose portion of the SER-252 study are expected in the first half of 2027.¶4
Cash and cash equivalents totaled $19.4 million as of September 30, 2026.¶6
- Operating expenses, three months ended September 30, 2026
- $8.0 million Compared with $6.4 million for the three months ended September 30, 2025¶2
- Net loss attributable to common stockholders, three months ended September 30, 2026
- $7.9 million Compared with net loss of $4.7 million for 2025¶3
- Net loss per basic and diluted share, three months ended September 30, 2026
- $(0.31) Compared with $(0.45) per share for 2025¶3
- Cash and cash equivalents as of September 30, 2026
- $19.4 million Liquidity as of the quarter end¶6
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $125.00K | $0.00 | $14.00K | $29.00K |
| Net Income | -$7.91M | -$4.59M | $1.41M | $1.75M |
| EPS Diluted | -$0.31 | -$0.45 | $0.13 | $0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Serina Therapeutics, Inc. · CIK 1708599 · Engraved from SEC EDGAR